Day: ខែ​ធ្នូ 2, 2025

ANKARA, Turkey, Dec 2, 2025 - (ACN Newswire via SeaPRwire.com) - GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, has announced new positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class, novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) in San Diego, CA (United States) today.SUL-238 was originally discovered by Sulfateq and has since been further developed through a collaborative effort of Sulfateq and GEN as a novel therapeutic in neurodegenerative diseases.This Phase 1 randomized, double-blind, placebo-controlled study evaluated the safety, tolerability, and pharmacokinetics (PK) after multiple-ascending doses (MAD) of orally administered SUL-238 in healthy elderly men and women (aged ≥40 years). The study included two cohort......

Partnership drives clinical research, hands-on student training, and access to cutting-edge medical technologiesPETALING JAYA, Malaysia, Dec 2, 2025 - (JCN Newswire via SeaPRwire.com) - AdipoLABs Co., Ltd. and Red & Blue Co., Ltd. from Korea, together with their Malaysian subsidiary, AdipoLABs Healthcare (M) Sdn Bhd, today officially opened the new AdipoLABs regional office for Asia-Pacific, marking a strategic expansion to strengthen its leadership in non- invasive healthcare and build a robust MedTech ecosystem in Malaysia and across ASEAN.As a research and development-focused medical company, its presence is expected to drive knowledge transfer, foster R&D collaboration, provide industry-standard training, and enhance the country’s preventive healthcare capabilities. Tocommemorate this milestone, the company also signed two Memoranda of Understanding (MoUs) with the University of Cyberjaya (UoC), formalising a partnership to advance healthcare innovation, clinical research, and talent develop......